Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 26, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("GSK Trust"). On November 25, 2003, Abacus (GSK) Trustees Limited transferred 20,407 Ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Consequently, Directors Dr. J-P Garnier and Mr. J D Coombe hold an interest in the shares held by the GSK Trust in the same capacity as other employees. No specific risks, contingencies, or unusual items regarding operations were disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust following the transfer of 20,407 shares.
- Confirm the specific allocation of shares to participants under the SmithKline Beecham Employee Share Option Plan 1991.
- Review the full annual report (Form 20-F) for comprehensive financial metrics, as this 6-K filing contains none.